The prognostic value of P53 and CA15.3 tumor markers in breast cancer patient

Abstract

Breast cancer is the second most prevalent malignancy among women. The cancer antigenCA 15-3 has been used as a putative serum marker of occult and recurring breast carcinoma.The p53 gene is mutated in human cancer. Immunohistochemistry reveals that the mutantp53 protein is more stable and has a longer half-life compared to the wild type. This studyaims to estimate the role of the p53 protein in diagnosing and confirming breast cancercompared to cancer antigen 15-3 (CA15-3.The current research involved 68 womendiagnosed with breast cancer who were aged 30-60 years old. The control group consistedof 10 healthy women. Before surgery, sera samples were collected. The Sandwich-ELISAtechnique measures the amount of p53 protein in sera. An immunoradiometric assay(IRMA) kit was used to measure the sera CA 15-3 levels. The study found a higher level ofCA15-3 In breast cancer patients (186.7±218) compared to healthy control groups(8.88±3.7). There are no significant associations between p53 protein levels and patientclinical features such as age and grade. Furthermore, the p53 protein value did not correlatewith serum CA 15-3.